Critical Mass: Paraquat Judge Warns Attorney Not to ‘Blow Up’ Settlement Talks; J&J’s Talc Bankruptcy Gambit Fails, Paving Way for Mass Dismissals
In this week’s edition of Law.com Class Actions: Critical Mass, Amanda Bronstad dives into two seismic developments shaking mass tort dockets: A federal judge’s stern rebuke to a star plaintiffs’ lawyer over paraquat settlement meddling, and Johnson & Johnson’s latest courtroom defeat that could torpedo thousands of talc cancer claims. With bellwether trials looming and billions at stake, these rulings highlight the high-wire act of mass litigation—where one rogue Zoom call or bankruptcy ploy can unravel years of negotiations.
Paraquat Poisoning MDL: Judge Orders Wagstaff to Explain ‘Recruitment’ Push Amid Confidential Talks
U.S. District Judge Nancy Rosenstengel isn’t mincing words in the paraquat multidistrict litigation: She’s summoned high-profile attorney Aimee Wagstaff to a November 14 showdown, demanding answers on a planned video conference that appears to rally plaintiffs for opting out of a potential global settlement. In a pointed order, Rosenstengel cautioned Wagstaff—once a member of the plaintiffs’ leadership committee who resigned in 2021 to pursue cases in Philadelphia—not to “blow up the settlement,” signaling frustration with efforts that could derail a confidential agreement between Syngenta and plaintiffs’ counsel.
The herbicide paraquat, a potent weed killer linked to Parkinson’s disease, has spawned over 5,000 lawsuits in the Southern District of Illinois MDL, with plaintiffs alleging exposure via farm work or home use triggered neurological harm. A $1.25 billion master settlement framework emerged in late 2024, backed by leadership but facing opt-out threats from dissident lawyers like Wagstaff, whose firm has secured bellwether wins in state court. Rosenstengel’s missive stems from a Wagstaff email inviting paraquat attorneys to discuss “options” around the deal, which the judge views as potential solicitation in violation of MDL confidentiality pacts.
“This is a classic leadership fracture,” Bronstad notes in her analysis. “Wagstaff’s push highlights the tension between maximizing client recovery and preserving class-wide leverage—especially with Syngenta’s $500M+ reserves hanging in the balance.” Sanctions loom if Wagstaff’s confab is deemed improper, but her defenders argue it’s protected advocacy. The hearing could force transparency on settlement terms, potentially accelerating opt-outs and splintering the MDL into state-court chaos.
For plaintiffs—often farmers and groundskeepers facing $1M+ lifetime care costs—this impasse delays justice in a litigation plagued by expert Daubert battles (another key witness struck last month). Economically, it spotlights agribusiness risks: Paraquat’s $1B annual U.S. market could face bans or hikes if litigation escalates, per USDA forecasts. Politically, it reignites EPA scrutiny (the agency reaffirmed safety in 2024 but under fire from advocacy groups). Technologically, emerging biomarkers for Parkinson’s detection could bolster future claims, but for now, Rosenstengel’s gavel demands unity—or else.
Talc Cancer Saga: Bankruptcy Dismissal Opens Door to Wholesale Case Tosses
Johnson & Johnson’s third bankruptcy Hail Mary for its talc woes crashed and burned on March 31, 2025, when U.S. Bankruptcy Judge Christopher Lopez dismissed the Red River Talc LLC Chapter 11 filing outright—paving the way for thousands of ovarian cancer and mesothelioma suits to proceed to trial or face outright dismissal. In a scathing 57-page opinion, Lopez lambasted the “Texas Two-Step” maneuver as bad faith, citing rushed voting (just days for 93,000 claimants), flawed solicitation, and J&J’s robust finances (a $400B market cap rendering distress “fictitious”).
This caps J&J’s serial flops: Two prior subsidiary bankruptcies (LTL Management in 2021 and 2023) were axed by the Third Circuit for the same sham-company sins. With the $10B prepack plan (backed by 85% of claimants) now DOA, J&J vows to “litigate and defeat these meritless claims” in state and federal courts, setting aside $7B for defenses. But plaintiffs’ lawyers like Andy Birchfield hail it as vindication: “No more dodging juries—our clients get their day.”
The fallout? Over 90,000 pending cases (mostly ovarian cancer from asbestos-tainted baby powder) could see waves of dismissals if plaintiffs can’t prove exposure or causation—J&J’s go-to playbook, succeeding in 16 of 17 trials since 2014. Yet recent verdicts sting: A California jury slapped J&J with a record $966M in October 2025 for a mesothelioma death, and Massachusetts awarded $42M in August. Bronstad warns: “Without bankruptcy’s shield, J&J faces trial tsunamis, but weak claims (e.g., no-use plaintiffs) risk mass pruning.”
For survivors—predominantly women alleging decades of dusted talc caused gynecological cancers—the shift means faster trials but higher dismissal risks, straining support networks amid $1,300/month treatments. Economically, it pressures J&J’s $200B pharma empire (stock dipped 5% post-ruling), fueling calls for FDA overhauls on talc safety. Politically, it’s a bipartisan flashpoint: House Dems probe J&J’s internal asbestos memos, while GOP eyes tort reform. Technologically, AI-scanned pathology slides could tip future causation fights, but for now, the tort system’s revival promises raw jury reckonings.
What’s Next? Paraquat’s November hearing could fracture settlements; talc’s post-dismissal wave hits dockets by Q1 2026. Bronstad’s radar: Watch for J&J appeals (Supreme Court shot slim) and paraquat expert rematches. In mass torts, unity’s fragile—but the gavel’s final.
By Sam Michael, drawing on Law.com’s Critical Mass insights
Follow and subscribe to us to increase push notifications.
Paraquat MDL settlement Wagstaff, Aimee Wagstaff sanctions Rosenstengel, J&J talc bankruptcy dismissal 2025, talc cancer cases dismissal risk, Johnson Johnson Red River Talc, ovarian cancer talc lawsuits, paraquat Parkinson’s MDL, talc MDL verdicts 2025, mass tort settlement opt-outs, J&J talc litigation update